← All trials
NCT05411705
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 6, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Jun 9, 2022
- Last posted
- Jun 28, 2022
- Enrollment
- 165
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dalian Medical UniversityLead sponsor
- Anqing Municipal HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
- People's Liberation Army of ChinaCollaborator
- Henan Medical UniversityCollaborator
- Henan Provincal People's HospitalCollaborator
- Dalian Medical UniversityCollaborator
- Peking UniversityCollaborator
- Dalian Medical UniversityOverall official - principal investigator
- Dalian Medical UniversityReponsible party - principal investigator
- Tianjin Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- Dalian Medical UniversitySponsor investigator
- Hebei UniversityCollaborator
- Dalian Medical UniversityOfficial
- Nantong UniversityCollaborator
- Bethune Charitable FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.